Neuropharmacological profile of EMD 57445, a σ receptor ligand with potential antipsychotic activity
- 1 November 1996
- journal article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 315 (3) , 235-243
- https://doi.org/10.1016/s0014-2999(96)00602-4
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- P-4-3 Central effects of EMD 57445, a new sigma receptor ligand with a potential antipsychotic activityEuropean Neuropsychopharmacology, 1995
- P-4-14 Pharmacology of the potential antipsychotic EMD 57445 in animals and humansEuropean Neuropsychopharmacology, 1995
- Pharmacological effects of rimcazole and 1,3-di-o-tolylguanidine, sigma receptor ligands, as potential antipsychotic agentsEuropean Neuropsychopharmacology, 1994
- Autoradiographic distribution of [3H](+)-pentazocine and [3H]1,3-di-o-tolylguanidine (DTG) binding sites in guinea pig brain: a comparative studyBrain Research, 1992
- Pharmacological specificity of some psychotomimetic and antipsychotic agents for the sigma and PCP binding sitesLife Sciences, 1988
- Classification and nomenclature of phencyclidine and sigma receptor sitesTrends in Neurosciences, 1987
- Evidence that the potential antipsychotic agent rimcazole (BW 234U) is a specific, competitive antagonist of sigma sites in brainLife Sciences, 1986
- Open label evaluation of the novel antipsychotic compound BW234U in chronic schizophrenicsDrug Development Research, 1985
- Psychotropic actions of BW 234U in the treatment of inpatient schizophrenics: A dose-range studyDrug Development Research, 1983
- Influence of amphetamine and scopolamine on the catalepsy induced by diencephalic lesions in ratsInternational Journal of Neuropharmacology, 1968